Assessment of intralesional injection of botulinum toxin type A in hypertrophic scars and keloids: Clinical and pathological study.

Keloids and hypertrophic scars are cosmetic problems with significant morbidity. Many clinical modalities were tried in order to modulate the disfigurement related to these pathologic scars. To evaluate the clinical and histopathological effects of Botulinum toxin type A (BTX-A) injection on keloids and hypertrophic scars. Twelve patients with keloids and 8 with hypertrophic scars were enrolled in this study. Botulinum toxin type A was injected intralesional (1 session/month) for three sessions. Clinical outcome was assessed via Vancouver Scar Scale (VSS), Observer Scar Assessment Scale (OSAS), and the Patient Scar Assessment Scale (PSAS). Histologic grading scores were used to assess the changes in the quality of collagen and elastic tissues and image analysis was used to detect their quantitative morphometric changes. This study showed a high statistically significant difference between baseline and the result after each of the three sessions of injection and 3, 6 months after the last session regarding VSS, OSAS, and PSAS with p value ≤0.001 for each. The study also showed that there was a statistically significant difference between the histopathologic findings before injection of BTX and 1 month after the third session regarding all parameters used. Botulinum toxin type A can be a good therapeutic maneuver for management of keloid and hypertrophic scars with significant clinical and histologic improvement.

Designing and fabrication of new VIP biosensor for the rapid and selective detection of foot-and-mouth disease virus (FMDV).

Foot and mouth disease virus (FMDV), is a highly contagious virus due to its ease of transmission. FMDV has seven genetically distinguished serotypes with many subtypes within each serotype. The traditional diagnostic methods of FMDV have demonstrated many drawbacks related to sensitivity, specificity, and cross-reactivity. In the current study, a new viral imprinted polymer (VIP)-based biosensor was designed and fabricated for the rapid and selective detection of the FMDV. The bio-recognition components were formed via electrochemical polymerization of the oxidized O-aminophenol (O-AP) film imprinted with FMDV serotype O on a gold screen-printed electrode (SPE). The overall changes in the design template have been investigated using cyclic voltammetry (CV), atomic force microscopy (AFM), Field emission-scanning electron microscopy (FE-SEM), and Fourier-transform infrared spectroscopy (FT-IR). Optimal conditions were achieved through investigating the capturing efficiency, binding stability, selectivity and life-time of the developed biosensor. The results depicted a high selectivity of the biosensor to the serotype O over all other genus serotypes A, SAT2 and Lumpy skin disease virus (LSDV), as well as, the inactivated serotype O. The limits of detection (LOD) and quantification (LOQ) were around 2 ng/mL and 6 ng/mL, respectively, in addition to the tested repeatability and reproducibility values with a variance coefficient of 1.0% and 3.6%, respectively. In comparison with the reference methods (ELISA and PCR), the analysis of saliva real samples using the developed affordable biosensor offered 50 folds lower LOD with the possibility of an on-line monitoring in the field with no prior sample treatment.